Nhs qipp medicines management implementation august 2010
NeLM news service DOH “Quality, Innovation, Productivity and Prevention (QIPP)” 2010/11 report on medicines management Source: Department of Health (DH) Date published: 28/07/2010 16:02 Summary by: Sheetal Ladva In response to the challenges of the current economic climate within the NHS, the Department of Health’s has focussed on identifying areas where it can simultaneously improve the quality of care and release substantial efficiency savings, by working at scale and pace across the NHS. This work is called ‘Quality, Innovation, Productivity and Prevention (QIPP)’. This QIPP report identifies some key therapeutic medicines management options for local implementation in 2010/11. It has been produced following a multidisciplinary scoping exercise, undertaken to identify a validated list of options for maximising efficient use of NHS spending on primary care prescribing, whilst maintaining quality, in the context of a challenging medium term financial position. The following topics have been identified for local implementation: 1. Renin-angiotensin system drugs - Review to ensure in line with NICE guidance. 2. Statins- Review high cost statins to ensure in line with NICE guidance. 3. Newer hypoglycaemics - In type 2 diabetes mellitus consider the risks and benefits of both tight glycaemic control and newer hypoglycaemic agents carefully. Review to ensure in line with NICE guidance. 4. Proton pump inhibitors (PPIs) - Review to ensure in line with NICE guidance and, if a PPI is required, that a low cost PPI is used unless it is ineffective or not tolerated. 5. Non-steroidal anti-inflammatory drugs (NSAIDs) - Review appropriateness of NSAID prescribing widely and on a routine basis. 6. Low dose antipsychotics in people with dementia - Review, and where appropriate revise, prescribing of low dose antipsychotics in people with dementia. 7. Long acting insulin analogues - Review to ensure in line with NICE guidance. 8. Self-monitoring of blood glucose in type 2 diabetes mellitus - Review to ensure in line with NICE guidance. 9. Clopidogrel – Review to ensure in line with NICE guidance. 10. Ezetimibe - Review to ensure in line with NICE guidance 11. Antibiotic prescribing – especially quinolones and cephlasporins - Review and, where appropriate, revise current prescribing practice and use implementation techniques to ensure prescribing is in line with Health Protection Agency guidance. 12. Hypnotics -Review to ensure in line with national guidance. 13. Orlistat -Review to ensure in line with the Summary of Product Characteristics (SPC) and NICE guidance. 14. High dose inhaled corticosteroids - Review use routinely in patients with asthma and COPD. 15. Alendronate -Promote use of generic alendronate as first line bisphosphonate for osteoporosis. See link for full report including the evidence behind the local implementation of the topics above. About this library entry Category: Department of Health (DH) | Medicines management | Prescribing and supply of medicines NeLM area: News QIPP report
Conducted at the Clinic for Dermatology and Dermatological Allergology A receding hairline and premature hair loss affect not just men but also repre-sent a worrisome development for women. With the onset of menopause, one out of three or four women will notice increased hair loss, which will ultimately lead to the thinning of hair if left untreated. Since the cause can not be remedied, women sy
(Actos cuja publicaça˜o é uma condiça˜o da sua aplicabilidade) DIRECTIVA 2000/31/CE DO PARLAMENTO EUROPEU E DO CONSELHO de 8 de Junho de 2000 relativa a certos aspectos legais dos serviços da sociedade de informaça˜o, em especial do comércio electro´nico, no mercado interno («Directiva sobre comércio electro´nico») O PARLAMENTO EUROPEU E O CONSELHO DA UNIA˜O EURO-(3)